comparemela.com

Latest Breaking News On - Thomas feldthus - Page 2 : comparemela.com

Saniona s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies

Saniona s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies
privataaffarer.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from privataaffarer.se Daily Mail and Mail on Sunday newspapers.

United statesBoehringer ingelheim gmbThomas feldthusProductos medixPalle christophersenChief executive officerAbuse regulation thisBoehringer ingelheim gmbhNasdaq stockholm small cap

Saniona publishes its interim report for the second quarter of 2022

Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Revenue was SEK 3.0 M Revenue was SEK 9.6 M Operating profit/loss was SEK -91.8 M Net profit/loss was SEK -88.6 M Operating. | August 25, 2022

Anna ljungThomas feldthusCarl johan sundbergThree months ended juneMonths ended juneChief executive officerAnita millandChief financialAnnual general meetingEmployees option programAbuse regulationandSecurities marketsSaniona ab publ stock exchangePress releaseM sanion se0005794617

Saniona AB: Saniona publishes its interim report for the second quarter of 2022

Three Months Ended June 30, 2022 (2021)Six Months Ended June 30, 2022 (2021)Revenue was SEK 3.0 M (1.9 M)Revenue was SEK 9.6 M (5.3 M)Operating profit/loss was SEK -91.8 M (-103.6 M)Net profit/loss

United kingdomAnna ljungThomas feldthusCarl johan sundbergThree months ended juneMonths ended juneChief executive officerAnita millandChief financialAnnual general meetingEmployees option programAbuse regulationandSecurities marketsNasdaq stockholm small cap

Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022

PRESS RELEASE August 18, 2022 Today, on August 18, 2022, an extraordinary general meeting was held in Saniona AB. A summary of the adopted resolution follows below. The resolution was

United kingdomThomas feldthusNasdaq stockholmNasdaq stockholm small

Saniona progresses its Kv7 epilepsy program into Lead

PRESS RELEASE August 16, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it has progressed its promising Kv7.

Thomas feldthusPalle christophersenLead optimization phaseNasdaq stockholm small capStockholm stock exchange sanionSaniona ab

vimarsana © 2020. All Rights Reserved.